Osteoporosis
What is Osteoporosis?
Osteoporosis is a bone disease characterized by decreased bone density and strength, which makes bones more fragile and prone to fractures. It often progresses without symptoms until a fracture occurs.
Causes of Osteoporosis
- Bone remodeling imbalance: With age, the rate of bone breakdown exceeds the rate of new bone formation.
- Hormonal changes: Reduced estrogen levels in women (especially post-menopause) and testosterone levels in men contribute to bone loss.
- Calcium and vitamin D deficiency: Essential nutrients for bone health; low levels can accelerate bone loss.
- Genetics: Family history of osteoporosis increases risk.
- Medical conditions: Such as hyperthyroidism, celiac disease, and rheumatoid arthritis.
- Medications: Long-term use of corticosteroids and certain other drugs can weaken bones.
Risk Factors
- Age: Risk increases as you get older, especially after 50.
- Gender: Women are more likely to develop osteoporosis than men.
- Family history: Higher risk if a parent or sibling has osteoporosis.
- Body frame size: Smaller body frames have less bone mass to draw from as they age.
- Diet: Low intake of calcium and vitamin D contributes to bone loss.
- Lifestyle choices: Sedentary lifestyle, smoking, and excessive alcohol use increase risk.
Symptoms of Osteoporosis
Osteoporosis is often called a “silent disease” because bone loss occurs without symptoms. When symptoms do appear, they may include:
- Back pain: Caused by a fractured or collapsed vertebra.
- Loss of height over time
- Stooped posture
- Bone fractures: Occur more easily, especially in the hip, spine, or wrist.
Diagnosis
- Bone density test (DEXA scan): The most common test to measure bone mineral density (BMD).
- Physical examination: Review of medical history and risk factors.
- Laboratory tests: To rule out other medical conditions that could cause bone loss.
Prevention Strategies
- Calcium-rich diet: Include dairy products, leafy greens, and fortified foods to maintain bone strength.
- Vitamin D intake: Sun exposure and foods like salmon and fortified milk help the body absorb calcium.
- Regular exercise: Weight-bearing and strength-training exercises can improve bone density.
- Avoid smoking: Smoking accelerates bone loss.
- Limit alcohol consumption: Excessive drinking can interfere with bone formation.
Treatment Options
- Medications:
- Bisphosphonates: Reduce bone loss and fracture risk (e.g., alendronate, risedronate).
- Monoclonal antibodies: Such as denosumab, which helps slow bone breakdown.
- Hormone-related therapy: Estrogen therapy can maintain bone density in postmenopausal women.
- Anabolic agents: Medications like teriparatide and abaloparatide that stimulate new bone formation.
- Calcium and vitamin D supplements: Ensure sufficient intake to support bone health.
- Lifestyle changes: Incorporating more physical activity and balanced nutrition into daily routines.
Complications of Osteoporosis
- Fractures: Most common and serious complication, especially in the hip and spine.
- Loss of mobility: Hip fractures can lead to reduced mobility and independence.
- Chronic pain: Can result from spinal fractures or bone damage.
- Height loss and spinal deformities: Fractures in the spine can lead to a curved or stooped posture.
- Increased risk of mortality: Especially after hip fractures in older adults.
9. References & Research
Historical Background
The term "osteoporosis" was coined by French pathologist Jean Lobstein in 1835, meaning "porous bone." Fuller Albright in the 1940s established the link between estrogen deficiency and postmenopausal bone loss, laying the groundwork for modern understanding of the disease. The development of dual-energy X-ray absorptiometry (DEXA) in the 1980s revolutionized diagnosis and screening.
Key Research Papers
- Black DM, Rosen CJ. Postmenopausal Osteoporosis. New England Journal of Medicine. 2016;374(3):254-262.
- Compston J, Cooper A, Cooper C, et al. UK clinical guideline for the prevention and treatment of osteoporosis. Archives of Osteoporosis. 2017;12:43.
- Rachner TD, Khosla S, Hofbauer LC. Osteoporosis: now and the future. The Lancet. 2011;377(9773):1276-1287.
- Black DM, Schwartz AV, Ensrud KE, et al. Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX). JAMA. 2006;296(24):2927-2938.
- Cummings SR, San Martin J, McClung MR, et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis (FREEDOM trial). New England Journal of Medicine. 2009;361(8):756-765.
- Eastell R, Rosen CJ, Black DM, et al. Pharmacological management of osteoporosis in postmenopausal women: an Endocrine Society Clinical Practice Guideline. Journal of Clinical Endocrinology & Metabolism. 2019;104(5):1595-1622.
- Saag KG, Petersen J, Brandi ML, et al. Romosozumab or alendronate for fracture prevention in women with osteoporosis (ARCH trial). New England Journal of Medicine. 2017;377(15):1417-1427.
- Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women (WHI). JAMA. 2002;288(3):321-333.
- Compston JE, McClung MR, Leslie WD. Osteoporosis. The Lancet. 2019;393(10169):364-376.
- Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. New England Journal of Medicine. 2001;344(19):1434-1441.
- Kanis JA, Cooper C, Rizzoli R, Reginster JY. European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporosis International. 2019;30(1):3-44.
- Khosla S, Hofbauer LC. Osteoporosis treatment: recent developments and ongoing challenges. The Lancet Diabetes & Endocrinology. 2017;5(11):898-907.